In-Licensing and Out-Licensing Opportunities

Philippines, Sri Lanka, Malaysia, Vietnam, and Peru – Why Taj Pharma Is the Best Partner

Granulation in Pharma Manufacturing
Granulation in Pharma Manufacturing

In today’s highly regulated and competitive global pharmaceutical landscape, strategic in-licensing and out-licensing partnerships have become the fastest and most efficient route for companies to expand market reach, accelerate product availability, and optimize portfolio value. For emerging and regulated markets alike, selecting the right pharmaceutical partner determines not only regulatory success but also long-term commercial sustainability.

Partner with Taj Pharma India Ltd., a WHO-GMP and PIC/S certified pharmaceutical manufacturer, offering CTD dossiers, branded generics, and long-term licensing partnerships.

At Taj Pharma India Ltd., we have positioned ourselves as a preferred in-licensing and out-licensing partner for pharmaceutical companies across Philippines, Sri Lanka, Malaysia, Vietnam, and Peru. With WHO-GMP, PIC/S, ISO 9001:2018, and GLP-compliant manufacturing, deep regulatory expertise, and a broad multi-therapeutic product portfolio, we provide an end-to-end solution for companies seeking speed, compliance, quality, and profitability.

Taj Pharma is a WHO-GMP certified pharmaceutical manufacturer in India offering in-licensing and out-licensing partnerships in Philippines, Sri Lanka, Malaysia, Vietnam, and Peru with CTD dossiers, branded generics, and flexible commercial models.

Product NameBrand NameTherapeutic CategoryDosage FormAvailable StrengthsBCS Class (Estimate)
Desvenlafaxine Extended ReleaseDESVEN-TAJ ERAntidepressant (SNRI)ER Tablets25 mg, 50 mg, 100 mgBCS Class I
MirtazapineMIRTAZ-TAJAntidepressant (NaSSA)Tablets30 mgBCS Class II
DuloxetineDULOX-TAJAntidepressant (SNRI)Delayed-Release Capsules30 mg, 60 mgBCS Class II
Amlodipine + Valsartan + HydrochlorothiazideAMLOVAL-H TAJAntihypertensive (CCB + ARB + Diuretic)Tablets10/160/12.5 mg, 10/160/25 mg, 10/320/25 mg, 5/160/12.5 mg, 5/160/25 mgBCS Class II / III (Combo)
Irbesartan + HydrochlorothiazideIRBE-H TAJAntihypertensive (ARB + Diuretic)Tablets150/12.5 mg, 300/12.5 mg, 300/25 mgBCS Class II / III
IvabradineIVAB-TAJAntianginal / Heart Rate ModulatorTablets5 mg, 7.5 mgBCS Class II
PramipexolePRAMI-TAJAnti-Parkinsonian (Dopamine Agonist)Tablets0.25 mg (250 mcg), 1 mgBCS Class I
RopiniroleROPI-TAJAnti-Parkinsonian (Dopamine Agonist)Tablets4 mg, 8 mgBCS Class I
VildagliptinVILDA-TAJAntidiabetic (DPP-4 Inhibitor)Tablets50 mgBCS Class III
Vildagliptin + MetforminVILDA-MET TAJAntidiabetic (DPP-4 Inhibitor + Biguanide)Tablets50/500 mg, 50/850 mg, 50/1000 mgBCS Class III
Mirtazapine Delayed ReleaseMIRTAZ-TAJ DRAntidepressant (NaSSA)Delayed-Release Tablets20 mg, 30 mgBCS Class II
TacrolimusTACRO-TAJImmunosuppressant (Calcineurin Inhibitor)Capsules0.5 mg, 1 mg, 5 mgBCS Class II
AzathioprineAZATH-TAJImmunosuppressant (Antimetabolite)Tablets50 mgBCS Class I
Mycophenolic AcidMYCO-TAJImmunosuppressant (Antiproliferative)Delayed-Release Tablets180 mg, 360 mgBCS Class II
Sacubitril + ValsartanSACUVAL-TAJHeart Failure Therapy (ARNI)Film-Coated Tablets24/26 mg, 49/51 mg, 97/103 mgBCS Class II
BetahistineBETA-TAJAntivertigo / Ménière’s Disease TherapyTablets24 mgBCS Class I
Sacubitril + Valsartan (Alt Strengths)SACUVAL-TAJHeart Failure Therapy (ARNI)Film-Coated Tablets48.6 mg, 51.4 mg, 226.2 mg, 24.3 mg + 25.7 mgBCS Class II
Methylphenidate Extended ReleaseMETHY-TAJ ERCNS Stimulant (ADHD Therapy)ER Tablets18 mg, 27 mg, 36 mgBCS Class I

Understanding In-Licensing and Out-Licensing in Pharma

What Is In-Licensing?

In-licensing refers to acquiring rights to manufacture, register, market, and distribute pharmaceutical products from another company in a defined territory. It enables local or regional companies to:

  • Rapidly expand portfolios
  • Reduce R&D risk
  • Launch high-value generics or specialty products
  • Enter new therapeutic segments

What Is Out-Licensing?

Out-licensing is the granting of product rights to a partner company for defined territories. It allows manufacturers like Taj Pharma to:

  • Monetize product assets
  • Expand global footprint
  • Accelerate market entry through local expertise
  • Build sustainable international revenue streams

At Taj Pharma, we actively support both in-licensing and out-licensing models with flexible commercial terms, regulatory support, and long-term partnership frameworks.


Why Focus on Philippines, Sri Lanka, Malaysia, Vietnam, and Peru?

These five countries represent high-growth pharmaceutical markets with rising healthcare demand, expanding insurance coverage, and increasing regulatory harmonization.

1. Philippines

  • Large generic medicine consumption
  • Strong demand for cardiovascular, CNS, anti-diabetic, and anti-infective drugs
  • High acceptance of Indian WHO-GMP products
  • Favorable pricing-volume dynamics

2. Sri Lanka

  • Government-driven generic substitution policies
  • Centralized procurement opportunities
  • Strong demand for essential medicines and chronic therapy drugs
  • High trust in Indian manufacturers

3. Malaysia

  • Semi-regulated ASEAN market
  • High standards for GMP and dossier quality
  • Strong private healthcare sector
  • Growing branded generics segment

4. Vietnam

  • One of the fastest-growing pharma markets in Southeast Asia
  • Increasing import of finished formulations
  • Government incentives for affordable generics
  • High demand for cardiovascular, diabetes, CNS, and oncology support drugs

5. Peru

  • Expanding public healthcare system
  • Growing demand for quality generics
  • Increasing registration of Indian products
  • Attractive margins for branded generics

Why Taj Pharma Is the Best In-Licensing and Out-Licensing Partner

1. World-Class Manufacturing Infrastructure

Taj Pharma operates WHO-GMP, PIC/S, ISO 9001:2018, and GLP-approved manufacturing facilities in India, producing:

  • Tablets and capsules
  • Oral liquids and suspensions
  • Dry syrups
  • Injectables
  • Specialty and modified-release formulations

This ensures global regulatory acceptability and consistent batch-to-batch quality.


2. Broad Multi-Therapeutic Product Portfolio

Our export-ready portfolio includes 500+ formulations across:

  • Cardiovascular (Amlodipine, Valsartan, Sacubitril/Valsartan, Ivabradine)
  • Diabetology (Metformin, Vildagliptin, Dapagliflozin combinations)
  • CNS (Desvenlafaxine, Duloxetine, Mirtazapine, Methylphenidate)
  • Anti-infectives
  • Gastroenterology
  • Immunosuppressants (Tacrolimus, Mycophenolate, Azathioprine)
  • Oncology supportive care
  • Pain management

This allows partners to build a complete branded or institutional portfolio from a single reliable source.


3. Strong Regulatory and Dossier Capabilities

We provide complete CTD/ACTD dossiers, including:

  • Module 1–5 documentation
  • Stability studies (Zone IVb compliant)
  • Bioequivalence support
  • DMF and API source documentation
  • Pharmacovigilance systems

This significantly reduces time-to-registration in:

  • Philippines FDA
  • NMRA Sri Lanka
  • NPRA Malaysia
  • DAV Vietnam
  • DIGEMID Peru

4. Flexible In-Licensing and Out-Licensing Models

Taj Pharma offers customized commercial structures, including:

  • Exclusive territorial rights
  • Semi-exclusive partnerships
  • Co-branding and private labeling
  • Technology transfer models
  • Contract manufacturing with licensing

This flexibility enables partners to optimize pricing, branding, and long-term market strategy.


5. Proven Export Track Record

We already export to Asia, Africa, CIS, Middle East, and Latin America, making Taj Pharma a trusted global supplier with:


Country-Wise Partnership Opportunities

Philippines

  • Branded generics in CVS, CNS, and anti-diabetics
  • Institutional tender supplies
  • Exclusive product in-licensing

Sri Lanka

  • Government tender-focused portfolios
  • Essential medicines
  • Long-term supply agreements

Malaysia

  • High-value modified-release formulations
  • Branded generics
  • Specialty therapeutic segments

Vietnam

  • Large-volume chronic therapy products
  • Private label manufacturing
  • Dossier-ready generics

Peru

  • Branded generics for retail market
  • Institutional supply
  • Immunosuppressant and cardiovascular portfolios

Commercial Benefits of Partnering with Taj Pharma

  • Lower cost of goods without quality compromise
  • Faster regulatory approvals
  • Reduced development risk
  • Strong product lifecycle management
  • Long-term portfolio scalability

Why Global Companies Prefer Taj Pharma

WHO-GMP and PIC/S compliant facilities
✔ Robust product portfolio
✔ Strong regulatory documentation
✔ Flexible licensing structures
✔ Transparent pricing
✔ Reliable long-term supply
✔ Proven international experience


Build Your Market Success With Taj Pharma

For pharmaceutical companies in Philippines, Sri Lanka, Malaysia, Vietnam, and Peru, the future belongs to those who move fast, partner smart, and deliver quality medicines consistently. Through our in-licensing and out-licensing partnerships, we empower companies to:

Cream Ointment Manufacturer in Vapi, Gujarat
Cream Ointment Manufacturer in Vapi, Gujarat
  • Launch high-quality generics rapidly
  • Expand portfolios efficiently
  • Achieve sustainable revenue growth
  • Strengthen long-term market presence

At Taj Pharma India Ltd., we do not just manufacture medicines — we build global pharmaceutical success stories.


Partner With Taj Pharma Today

Whether you are seeking in-licensing opportunities to expand your product range or out-licensing partnerships to bring high-quality Indian formulations into your market, Taj Pharma is your most reliable and profitable partner.

Contact Taj Pharma India Ltd.
📧 info@tajpharma.com
🌐 www.tajpharmaindia.com